Cipla recalls 4,800 bottles of anti-HIV tablets from American market

Cipla is recalling 4,800 bottles of Nevirapine extended-release tablets used for the treatment of HIV from the American market.

As per the latest Enforcement Report by the United States Food and Drug Administration (US FDA), the reason for the recall of the bottles is ‘failed dissolution specifications’.

Nevirapine extended-release tablets, 400 mg in the 30-count bottle have been manufactured by Cipla at its Goa facility for Cipla USA, it added.

The US health regulator has not yet classified the voluntary recall by the company, the report said.

Register as Visitor to CPhI China 2019!

-----------------------------------------------------------------------
Editor's Note:

To apply for becoming a contributor of En-CPhI.cn,

welcome to send your CV and sample works to us,

Email: Julia.Zhang@ubmsinoexpo.com.